Read more
Malignancies originating from the urogenital tract account for about 20% of all solid neoplasias. The various tumor types, including carcinoma of the prostate, transitional cell carcinoma, renal cell carcinoma, and testicular germ cell tumors, differ widely in terms of biological features, in cidence and appearance, diagnostic work-up and manage ment. It is not surprising that this complexity of urologic oncology with its related problems has increasingly attracted both experimental investigators and clinical experts. Only time will tell whether the achievements that today are con sidered· as progress will turn out to be significant contribu tions towards the ultimate goal: the cure of the patients' life-threatening diseases with little or no side effects. How ever, many innovations and improvements have already taken place in the field of urologic oncology within recent years. The high pace of innovative development requires continuous, thorough, and critical updating of our kowledge so that persisting deficits can be defined: the basic require ment for posing new scientific questions. The following examples may serve to illustrate the recent developments and the resulting new problems and questions: Recently, it has become evident that carcinoma of the prostate must be detected earlier to enable us to cure more of the affected patients in the future than currently.
List of contents
Carcinoma of the Prostate.- Screening for Carcinoma of the Prostate: Epidemiological and Methodological Aspects.- Screening for Carcinoma of the Prostate in a Randomly Selected Population.- Clinical Staging in Carcinoma of the Prostate: Current Aspects.- Radical Prostatectomy for Carcinoma of the Prostate: Long-Term Results.- Adjuvant Therapy After Radical Prostatectomy.- Endocrine Therapy of Advanced Prostatic Cancer.- Chemotherapy of Prostatic Carcinoma.- Renal Cell Carcinoma.- Organ-Sparing Excision of Renal Cell Carcinoma.- Renal Cell Carcinoma with Vena Caval Extension: Operative Management.- The Role of Cytokines in the Therapy of Renal Cell Carcinoma.- Superficial Bladder Cancer.- Intravesical Instillation Therapy: Alternatives Treatments.- When Should We Stop Intravesical Treatment in Patients with Superficial Bladder Cancer?.- Superficial Bladder Cancer: Primary Treatment with TUR with or without Laser-Coagulation.- Immunocytology as a Possible Marker to Identify Patients Who Require Prophylaxis.- Invasive Bladder Cancer.- Image Analysis DNA Cytometry of Bladder Cancer.- Radical Cystectomy: The Potential for Cure and Reconstruction.- Current Concepts in Urinary Diversion: The Ileal Neobladder.- Neoadjuvant Versus Adjuvant Chemotherapy in Invasive Bladder Cancer.- Radiochemotherapy for Invasive Carcinoma of the Bladder.- Germ Cell Tumors.- Treatment of Local Regional Disease.- Anatomic Study and Operative Approach to Retroperitoneal Bilateral Nerve-Preserving Lymphadenectomy.- Management of Early Stages of Testicular Carcinoma: The Current Status.- The Evolving Role of Chemotherapy of Germ Cell Tumprs.
About the author
Rolf Ackermann wurde 1952 in Duisburg, Deutschland geboren und war als Journalist und Korrespondent bei zahlreichen namhaften Zeitungen (Die Zeit, FAZ) und im Rundfunk (WDR, NDR). Langjährige Aufenthalte in Ost- und Westafrika haben ihn zu einem versierten Afrika-Kenner gemacht. Heute ist Ackermann ausschließlich als Schriftsteller tätig und lebt hauptsächlich in Wien und Namibia.
Prof. Dr. med. Volker Diehl, absolvierte eine Ausbildung in Innerer Medizin, klinischer Virologie und Hämato-Onkologie am Children's Hospital in Philadelphia, am Karolinska Institut in Stockholm und an der Med. Hochschule Hannover. Bis 1983 arbeitet er am Aufbau der Arbeitsgruppe für internistische Onkologie an der Med. Hochschule Hannover, seit 1983 ist er Ordinarius für Innere Medizin in Köln. Seine Arbeits- und Forschungsschwerpunkte sind: Innere Medizin, Hämatologie, Onkologie, Infektionskrankheiten und Immunologie. Seit 1994 ist er Mitglied im Editorial Board des NEW ENGLAND JOURNAL OF MEDICINE, 1995- 2001 war er Vorsitzender der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO),1999 war er Vorsitzender der Deutschen Gesellschaft für Innere Medizin (DGIM).
